Engitix appoints Sonia Quaratino as CMO
UK biotech Engitix, which is pioneering extracellular matrix (ECM)-driven drug discovery, today announced the appointment of Dr Sonia Quaratino in the newly created role of executive vice president, chief medical officer (CMO).
With more than 35 years of experience spanning immunology and oncology research, clinical development, and strategic leadership across biotechnology, pharmaceutical companies, and academia, Dr Quaratino brings deep expertise in chronic inflammatory diseases, autoimmunity, and oncology. Her scientific interests include the pathogenic mechanisms underlying chronic inflammatory conditions and the interface between inflammation, fibrosis and cancer - areas closely aligned with Engitix’s mission to deliver transformative therapies using Engitix’s proprietary human‑derived ECM platform.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze